Skip to main content

Start-up Illumigen Biosciences Develops New Genome Analysis Platform

NEW YORK, Feb 1 – Illumigen Biosciences, a start-up applied genomics company in Seattle, Wash., has unveiled a new computing platform for analyzing the human genome, the company said Thursday.

The system, GeneLamp, compares experimental data from Illumigen’s in-house laboratories with data from “a variety” of genomics databases to search for drug targets, according to the company.

The system will be incorporated into Illumigen's in-house experiments, which identify DNA sequence and gene expression data using proprietary population access programs.

“This program aims to speed our discovery efforts by increasing the efficiency with which we can evaluate and prioritize promising new drug targets,” Charles Magness, Illumigen's chief information officer, said in a statement.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.